4536 — Santen Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual cashflow statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	6,645	27,189	-14,983	26,703	35,853
Depreciation
Non-Cash Items	46,010	8,253	47,577	15,743	12,199
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-30,615	-6,454	-12,696	12,025	-5,072
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	38,808	46,043	37,147	72,649	60,928
Capital Expenditures	-23,804	-35,841	-24,588	-10,687	-11,019
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-29,551	672	-2,189	4,542	2,796
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-53,355	-35,169	-26,777	-6,145	-8,223
Financing Cash Flow Items	148	147	445	217	0
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-16,685	5,557	-37,220	-34,031	-53,307
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-28,542	20,125	-25,111	36,679	-1,585